Quantum BioPharma Ltd. (NASDAQ: QNTM), a biopharmaceutical company developing therapies for neurodegenerative, metabolic and alcohol misuse disorders, has invented unbuzzd, a supplement drink designed to support alcohol metabolism. The company retains royalty and equity interests in the consumer brand. Earlier this month, Men's Fitness reviewed the unbuzzd clinical trial and described the early study findings as "promising." The magazine noted that "a small clinical trial found improvements in alcohol readings, alertness, and headache symptoms . . . [offering] early encouragement." Researchers reported lower estimated blood alcohol concentrations at several time points, along with improved self-rated alertness and lower headache severity among participants.
For operators in the alcohol recovery space, the stakes reach beyond the morning after. Most recovery drinks promise relief after a night out, yet few have been tested against a placebo in a registered human trial. One that has is now getting a close look from a major fitness publication. The Men's Fitness coverage brings mainstream attention to a product that, if further trials confirm the early signals, could reshape how consumers and retailers evaluate recovery beverages. The article also provides a Read More>> link for the full story.
Quantum BioPharma's dual role as a biopharmaceutical developer and brand interest holder means the trial results could have implications for both its pipeline and its consumer-facing royalty stream. The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM. More details about the company can be found through Quantum BioPharma (NASDAQ: QNTM).
The announcement was distributed through MissionIR, a specialized communications platform focused on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. MissionIR is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution and a full array of tailored corporate communications solutions. For more information, visit www.MissionIR.com. Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer.
